AstraZeneca Could Seek New Indication For Iressa In Europe
This article was originally published in Pharmaceutical Approvals Monthly
AstraZeneca Iressa European Marketing Authorization Application withdrawn following the non-small cell lung cancer therapy’s failure to show a survival benefit in recent study. FDA is expected to provide an update on the status of gefitinib’s Subpart H approval in January or February
You may also be interested in...
Results of an initial Phase II study aimed at identifying responders to AstraZeneca's non-small cell lung cancer agent Iressa suggest further research could support approval in a subpopulation, researchers said at the recent American Society of Clinical Oncology meeting in Orlando, Fla
AstraZeneca will submit additional data for Symbicort inhalation delivery device. Hold-up comes in wake of setbacks for Iressa, Exanta and Crestor